• Type:
  • Category:

BRAIN Biotech AG Financial Results H1 2021 / 22 | Highlights, ESG and Mid-Term Targets with IR

Share

BRAIN Biotech AG H1 2021/22: Key Takeaways

Overview of Brain Biotech AG’s H1-22 Highlights and More

IR Michael Schneiders provides an overview of Brain Biotech AG’s H1-22 Highlights, PHA121, Incubator Exits, and more in this financial results presentation. He highlights the Q2-Highlights and the company’s commitment to ESG+. Michael also shares five key points related to ESG+ and the company’s targets for 2032/2050.

 

ESG+ Commitments and Targets

Key Points Related to ESG+ and Targets for 2032/2050

Michael shares five key points related to ESG+ and the company’s targets for 2032/2050, demonstrating the company’s commitment to sustainable and responsible business practices.

 

Exploring ESG Opportunities and Brain Incubator Projects

The ESG Opportunity

Discussion on the ESG Opportunity, exploring the potential and significance of ESG in the current market and future prospects.

 

Brain Incubator and Its Projects

Michael discusses the Brain Incubator, which includes exciting projects like the Urban Mining Project and Genome Editing, showcasing the innovative approaches and initiatives taken by Brain Biotech AG.

 

Analysis of H1 2021/22 Financial Highlights

Michael analyses the H1 2021/22 Financial Highlights, including cash and cash flow, long-term revenue growth trajectory, and the impact of Covid, Supply Chain, and Inflation, providing insights into the financial stability and challenges faced by Brain Biotech AG.

 

Concluding with FY21/22 Guidance and Mid-Term Targets

Finally, Michael concludes the presentation by providing FY21/22 Guidance and Mid-Term Targets for Brain Biotech AG. Overall, this presentation is an excellent resource for anyone interested in learning more about Brain Biotech AG and its financial performance, ESG commitments, and prospects.

Chapters
  • Brain at a Glance
  • Group Overview
  • Q2-Highlights
  • ESG+: 5 Key Points
  • ESG+ Targets 2032/2050
  • The ESG Opportunity
  • Brain Incubator
  • Urban Mining Project
  • Genome Editing
  • H1 2021/22 Financial Highlights
  • Cash & Cash Flow
  • Long-Term Revenue Growth Trajectory
  • Covid, Supply Chain and Inflation
  • FY21/22 Guidance, Mid-Term Targets
Resources
Presentation
BRAIN Biotech Video Hub
Podcast
Host
michaelschneiders - BRAIN Biotech AG Financial Results H1 2021 / 22 | Highlights, ESG and Mid-Term Targets with IR -%sitename%

Michael Schneiders
IR | BRAIN Biotech AG

Linkedin Envelope
Share
T&C:

This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

Continuing the Journey: More Presentations

Discover Additional Elevator Pitches

Release Date

May 30, 2022

Duration

18:08

Director

Reviews for BRAIN Biotech AG Financial Results H1 2021 / 22 | Highlights, ESG and Mid-Term Targets with IR
There are currently no reviews for BRAIN Biotech AG Financial Results H1 2021 / 22 | Highlights, ESG and Mid-Term Targets with IR
COMPANIES:

Germany:

Austria:

Estonia:

Finland:

France:

Italy:

Poland:

Spain:

PRESENTATIONS:
INDUSTRIES:
Linkedin Twitter Instagram Podcast Envelope Whatsapp

(c) seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESG 

Unlock the insights of top publicly listed companies with seat11a.com

Elevate your understanding with powerful Elevator Pitches, Deep-Dive Presentations, and in-depth Financial Analysis

Scroll to top